Phase 2 N=129 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Peripheral T-cell Lymphoma
Primary: Objective Response Rate — 25.8 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer · Brain Cancer
Primary: Median Survival — 11.8 months
Phase 2 N=42 Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer
Gastric Cancer
Primary: 2-month Response Rate — 25 percentage of participants
Phase 2 N=25 Defibrotide TMA Prophylaxis Pilot Trial
Thrombotic Microangiopathies
Primary: Percent of Total Doses of Defibrotide That Were Missed [Feasibility] — 0.7 percentage of missed doses
Phase 3 N=123 A Physical Dependence Study in Schizophrenia
Schizophrenia
Primary: Maximum 3-Day Moving Average (MA) of the Discontinuation Symptom Checklist-Modified Rickels Total Score — 13.23; 11.50 units on a scale — p=0.170
N/A N=528 Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism
Autism
Primary: Mean Changes of Aberrant Behavior Checklist-Japanese Version (ABC-J) Irritability Subscale Scores From Baseline. — 19.8; 14.7; 12.9; 12.7 score on a scale
Phase 2 N=81 Cardiovascular Effects of COVID-19
COVID-19
Primary: Hospital Length of Stay (LOS) — 5; 10; 25 days
Phase 1 N=9 Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Number of Patients With Dose Limiting Toxicities (DLTs) — 0 Participants
Phase 2 N=20 Efficacy, Safety and Local Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers
Healthy Subjects
Primary: Number of Participants Gaining Full Conjunctival Anesthesia of the Ocular Surface — 61; 2 Participants
N/A N=154 Young Men and Media Study
Sexual Behavior
Primary: Study Feasibility Based on the Overall Recruitment Rate — 36.5 overall recruitment rate
Phase 2 N=378 Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Uveal Melanoma
Primary: Efficacy: Overall Survival — 21.7; 16.0 Months — p=<0.0001
Phase 4 N=5,260 INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
Heart Failure · Myocardial Infarction
Primary: All-Cause Death or Cardiopulmonary Hospitalization Within Each Vaccination Season — 975; 924 Participant-Seasons — p=0.21
Early Phase 1 N=388 Innovative Tools to Expand HIV Self-Testing
HIV/AIDS · Sexually Transmitted Diseases
Primary: Uptake of HIV Self-testing Over the 3 Months Follow-up — 19; 7; 24; 4 Participants — p=<0.05
Phase 2 N=80 Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Systemic Lupus Erythematosus
Primary: Change in Vascular Function and Cardiometabolic Risk as Measured by Left CAVI at Month 3 — -0.32; 0.09 unitless
N/A N=21 Fenestrated AAA Endovascular Graft Post-Approval Study
Abdominal Aortic Aneurysm (AAA) · Aorto-iliac Aneurysm · Juxtarenal Aneurysm
Primary: Treatment Success : AAA Related Mortality — 0 Participants